<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00769938</url>
  </required_header>
  <id_info>
    <org_study_id>RDC-2008-03</org_study_id>
    <nct_id>NCT00769938</nct_id>
  </id_info>
  <brief_title>WOEST ( What is the Optimal antiplatElet &amp; Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing)</brief_title>
  <acronym>WOEST</acronym>
  <official_title>What is the Optimal antiplatElet &amp; Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>R&amp;D Cardiologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>R&amp;D Cardiologie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the hypothesis that the combination warfarin &amp; clopidogrel 75 mg/day is
      superior to triple therapy (warfarin + clopidogrel 75mg/day + aspirin 80mg/day) with respect
      to bleeding complications while equally safe with respect to the prevention of thrombotic
      complications in patients with both indications for warfarin use and dual antiplatelet
      (clopidogrel 75mg/day + aspirin 80mg/day) treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic oral antithrombotic treatment is necessary in patients with mechanical heart valves
      and in the majority of patients with atrial fibrillation. When these patients have to undergo
      Percutaneous Coronary Intervention (PCI) with stenting, there is also an indication for
      treatment with aspirin and clopidogrel. However, triple therapy is known to augment the risk
      for bleeding complications.Unfortunately, no prospective data are available to solve this
      issue. Nevertheless, it all comes down to finding the ideal therapy in patients with both
      atrial fibrillation and percutaneous intervention to prevent thrombotic complications (e.g.
      stent thrombosis) without increasing the risk of bleeding. This prospective randomised study
      will assess the hypothesis that in patients on warfarin therapy and indication for elective
      percutaneous intervention, the combination warfarin &amp; clopidogrel 75 mg/day is superior to
      triple therapy treatment in reducing the risk of bleeds while equally safe with respect to
      the prevention of thrombotic complications
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The combined end point of minor, moderate or major bleeding complications during the initial hospitalization &amp; one year follow-up. (TIMI &amp; GUSTO criteria).</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The combined event of death, myocardial infarction, stroke, systemic embolization &amp; target vessel revascularisation and the individual components of the composite primary and secondary endpoints.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">573</enrollment>
  <condition>Anticoagulants</condition>
  <condition>Platelet Aggregation Inhibitors</condition>
  <condition>Stents</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Aspirin + clopidogrel + oral anticoagulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral anticoagulants + clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PCI (percutaneous coronary intervention)</intervention_name>
    <description>only patients scheduled for PCI can be included tough this intervention would also take place without this study. What we want to study is the difference in outcome after a little change in the antithrombotic treatment</description>
    <arm_group_label>Aspirin + clopidogrel + oral anticoagulation</arm_group_label>
    <arm_group_label>Oral anticoagulants + clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients is on oral anticoagulation therapy and this will be continued throughout the
             period of 1 year-and deployment of at least 1 coronary stent (bare metal stent (BMS)
             or drug eluting stent (DES)). -age of more than 18 years

        Exclusion Criteria:

          -  cardiogenic shock,

          -  contra-indication for aspirin or clopidogrel

          -  allergy to aspirin or clopidogrel,

          -  documented peptic ulcer disease within the previous six months,

          -  pregnancy and

          -  previous intracerebral haemorrhage or

          -  significant thrombocytopenia (platelet count &lt; 50x10 9/L).

          -  major bleeding according to timi criteria within the past 12 months

          -  age &gt; 80 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>OLV Aalst</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZOL</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Middelares</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ KU Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MCA Alkmaar</name>
      <address>
        <city>ALkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zuiderziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Twee Steden Ziekenhuis</name>
      <address>
        <city>Tlibrug</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala klinieken</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.ahjonline.com/article/PIIS0002870309007182/abstract</url>
    <description>trial design</description>
  </link>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2008</study_first_submitted>
  <study_first_submitted_qc>October 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2008</study_first_posted>
  <last_update_submitted>January 12, 2013</last_update_submitted>
  <last_update_submitted_qc>January 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>R&amp;D Cardiologie</investigator_affiliation>
    <investigator_full_name>W. Dewilde</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Percutaneous coronary stenting</keyword>
  <keyword>Bleeding complications</keyword>
  <keyword>Triple therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

